Our systems have detected that you are using a computer with an IP address located in the USA.
If you are currently not located in the USA, please click “Continue” in order to access our Website.

Local restrictions - provision of cross-border services

Swissquote Bank Ltd (“Swissquote”) is a bank licensed in Switzerland under the supervision of the Swiss Financial Market Supervisory Authority (FINMA). Swissquote is not authorized as a bank or broker by any US authority (such as the CFTC or SEC) neither is it authorized to disseminate offering and solicitation materials for offshore sales of securities and investment services, to make financial promotion or conduct investment or banking activity in the USA whatsoever.

This website may however contain information about services and products that may be considered by US authorities as an invitation or inducement to engage in investment activity having an effect in the USA.

By clicking “Continue”, you confirm that you have read and understood this legal information and that you access the website on your own initiative and without any solicitation from Swissquote.

AC Immune

Alzheimer's within the line of sight

Will a small Lausanne-based company succeed in an area where pharma giants have been stuck for years? In 2016, two big US laboratories, Eli Lilly and Merck, announced, one right after the other, that they were giving up on their most advanced treatment for Alzheimer’s following inconclusive clinical trials. Since then, AC Immune has been in a perfect position to become the first pharma to market an Alzheimer’s drug.

“We recommend purchasing shares in AC Immune,” said Lorenzo Biasio, analyst at Credit Suisse, “as we like its diversified pipeline of treatments for Alzheimer’s, one of the most expensive diseases in the world, one that currently does not have decent treatment options.” Characterised by a progressive destruction of neurons, Alzheimer’s disease affects approximately 30 million people around the world, according to the World Health Organization. This number is expected to triple by 2050, notably because of the ageing global population.

Compared to its competitors, the company is ahead, with five molecules in development: “AC Immune stands out because it has a portfolio of several drug candidates that correspond with the various expected treatments,” said Biasio. The company also tests diagnostic tools for Alzheimer’s and Parkinson’s, as well as molecules – at a lesser stage of development – to treat Parkinson’s, Down’s Syndrome and glaucoma.

AC Immune

The Lausanne-based firm develops treatments and diagnostic tools to combat neurodegenerative diseases

  • Foundation: 2003
  • Headquarter: Lausanne (VD)
  • Revenues: CHF 23.2 Million (2016)
  • Effectives: 80